Stay updated on Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial page.

Latest updates to the Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThese changes are minor editorial updates to the Publications section, noting that PubMed publications are automatically populated, and the page revision has moved from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedThe government funding status notice was removed from the page. This change does not modify the study details, eligibility criteria, outcomes, or other substantive content.SummaryDifference0.2%

- Check34 days agoChange DetectedNo substantive updates were detected; the Study Details, Eligibility Criteria, Interventions, and Outcome measures appear unchanged between versions.SummaryDifference0.3%

- Check63 days agoChange DetectedUpdate includes a critical operating status notice and a new software version (v3.2.0), indicating updated deployment with potential service impact; previous version reference (v3.1.0) was removed.SummaryDifference3%

- Check70 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

- Check84 days agoChange DetectedRevision: v3.0.2 replaces v3.0.1; Back to Top UI element removed.SummaryDifference0.2%

Stay in the know with updates to Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial page.